Table IV.

Clinicopathological characteristics and expression of EHD1, EGFR, CAV-1 and RAB11FIP3 by immunohistochemistry.

		EGFR, n			EHD1, n			CAV-1, n			RAB11FIP3, n
Characteristic	n	Positive	Negative	P-value	Positive	Negative	P-value	Positive	Negative	P-value	Positive	Negative	P-value
Sex				NS			NS			NS			NS
Male	8	5	3		6	2		5	3		7	1
Female	64	45	19		47	17		58	6		54	8
Male:female ratio	1:8
Age, years				NS			NS			NS			NS
<45	46	30	16		37	9		40	6		42	4
≥45	26	20	6		16	10		23	3		21	5
Tumor size, cm				NS			0.011a			0.013a			NS
<2	52	37	15		34	18		49	3		44	8
≥2	20	13	7		19	1		13	6		19	1
Lymph node metastasis				0.027a			0.020a			NS			NS
No	49	30	19		32	17		41	8		45	4
Yes	23	20	3		21	2		22	1		18	5
EGFR							0.003b			0.004b			NS
Positive	50				42	8		48	2		45	5
Negative	22				11	11		15	7		18	4

EGFR, EHD1 and RAB11FIP3 were assessed using χ² tests. CAV-1 was assessed used a Continuity Correction test.

^aP<0.05

^bP<0.01. NS, not significant; EHD1, EH domain-containing 1; EGFR, epidermal growth factor receptor; RAB11FIP3, RAB11 family interacting protein 3; CAV-1, caveolin-1.